Biosketch
Mark Cragg is Professor of Experimental Cancer Biology in the School of Cancer Sciences at the University of Southampton Faculty of Medicine. He is a member of the Antibody and Vaccine Group, joint Deputy Head of School Research in Cancer Sciences and Director of the MRC DTP in Translational Biomedical Sciences. His research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules, with a particular interest in Fc receptors and TNFR family members. The aim is to understand how these therapeutics delete tumour cells, how resistance occurs, and how it might be overcome through antibody engineering.
Throughout the strategy undertaken is highly translational with iterative cycling between in vitro experiments, appropriate in vivo model systems, and primary clinical material. He sits on advisory boards for several charities, institutes and companies and has published over 200 research papers. In 2024, he was made a Fellow of the Academy of Medical Sciences in recognition of his contribution to the development of antibody immunotherapy.
Link to the University of Southampton webpage
Prof. Cragg will give lectures and interact with PRIMA Centre members and the local scientific community in Oslo. External researchers who are interested in meeting with Prof. Cragg can contact PRIMA